Nucresiran + Sterile Normal Saline (0.9% NaCl)

Phase 3Recruiting

3 views this week 0 watching⚡ Active🏛️Featured in Big Pharma Pipeline

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Transthyretin Amyloidosis With Cardiomyopathy

Conditions

Transthyretin Amyloidosis With Cardiomyopathy

Trial Timeline

Jul 2, 2025 → Nov 30, 2032

NCT ID

NCT07052903

About Nucresiran + Sterile Normal Saline (0.9% NaCl)

Nucresiran + Sterile Normal Saline (0.9% NaCl) is a phase 3 stage product being developed by Alnylam Pharmaceuticals for Transthyretin Amyloidosis With Cardiomyopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07052903. Target conditions include Transthyretin Amyloidosis With Cardiomyopathy.

What happened to similar drugs?

3 of 18 similar drugs in Transthyretin Amyloidosis With Cardiomyopathy were approved

Approved (3) Terminated (0) Active (15)

✅tafamidis megluminePfizerApproved

✅TafamidisPfizerApproved

✅AcoramidisBayerApproved

🔄Eplontersen + PlaceboAstraZenecaPhase 3

🔄EplontersenAstraZenecaPhase 3

🔄Eplontersen + PlaceboAstraZenecaPhase 3

🔄NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07052903	Phase 3	Recruiting	Jul 2, 2025	Nov 30, 2032	Transthyretin Amyloidosis With Cardiomyopathy

Competing Products

20 competing products in Transthyretin Amyloidosis With Cardiomyopathy

See all competitors

Product	Company	Stage	Hype Score
Eplontersen Solution for Injection	AstraZeneca	Phase 1	29
Eplontersen + Placebo	AstraZeneca	Phase 3	44
Treatment of transthyretin (ATTR) amyloidosis in observational study setting	AstraZeneca	Pre-clinical	33
Eplontersen	AstraZeneca	Phase 3	47
Eplontersen + Placebo	AstraZeneca	Phase 3	44
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 3	47
NNC6019-0001	Novo Nordisk	Phase 2	39
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 2	35
Coramitug	Novo Nordisk	Phase 1	36
Tafamidis	Pfizer	Pre-clinical	26
Tafamidis	Pfizer	Pre-clinical	30
tafamidis meglumine	Pfizer	Approved	43
Fx-1006A	Pfizer	Phase 2	35
Tafamidis	Pfizer	Phase 3	40
Tafamidis 61 milligrams	Pfizer	Pre-clinical	26
Treatment for TTR amyloidosis + Treatment for TTR amyloidosis	Pfizer	Pre-clinical	26
Vyndaqel	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Phase 3	40
Tafamidis	Pfizer	Approved	43
Tafamidis	Pfizer	Pre-clinical	26